ATE226254T1 - Reagenz zur behandlung von arthritischen zustaenden - Google Patents

Reagenz zur behandlung von arthritischen zustaenden

Info

Publication number
ATE226254T1
ATE226254T1 AT95901907T AT95901907T ATE226254T1 AT E226254 T1 ATE226254 T1 AT E226254T1 AT 95901907 T AT95901907 T AT 95901907T AT 95901907 T AT95901907 T AT 95901907T AT E226254 T1 ATE226254 T1 AT E226254T1
Authority
AT
Austria
Prior art keywords
reagent
treatment
arthritic conditions
arthritic
conditions
Prior art date
Application number
AT95901907T
Other languages
English (en)
Inventor
Kenneth G Draper
Pamela Pavco
James Mcswiggen
John Gustofson
Original Assignee
Ribozyme Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ribozyme Pharm Inc filed Critical Ribozyme Pharm Inc
Application granted granted Critical
Publication of ATE226254T1 publication Critical patent/ATE226254T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24017—Stromelysin 1 (3.4.24.17)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/121—Hammerhead
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/122—Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
AT95901907T 1993-11-12 1994-11-10 Reagenz zur behandlung von arthritischen zustaenden ATE226254T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15248793A 1993-11-12 1993-11-12
PCT/US1994/013129 WO1995013380A2 (en) 1993-11-12 1994-11-10 Method and reagent for treatment of arthritic conditions

Publications (1)

Publication Number Publication Date
ATE226254T1 true ATE226254T1 (de) 2002-11-15

Family

ID=22543137

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95901907T ATE226254T1 (de) 1993-11-12 1994-11-10 Reagenz zur behandlung von arthritischen zustaenden

Country Status (7)

Country Link
EP (1) EP0728205B1 (de)
JP (1) JPH09504949A (de)
AT (1) ATE226254T1 (de)
AU (1) AU704687B2 (de)
CA (1) CA2175824A1 (de)
DE (1) DE69431564D1 (de)
WO (1) WO1995013380A2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2207593A1 (en) * 1994-12-13 1996-06-20 John Gustofson Method and reagent for treatment of arthritic conditions, induction of graft tolerance and reversal of immune responses
DE69633272T2 (de) 1995-02-08 2005-09-08 Takara Bio Inc., Otsu Methoden zur Krebsbehandlung und -kontrolle
EP1408111B1 (de) * 1995-10-26 2010-06-09 Sirna Therapeutics, Inc. Verfahren und Reagenz zur Behandlung von Krankheiten die von der Konzentration des Rezeptors für den Wachstumsfaktor der vaskulären Endothelzellen verursacht werden
US6346398B1 (en) 1995-10-26 2002-02-12 Ribozyme Pharmaceuticals, Inc. Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
US7034009B2 (en) 1995-10-26 2006-04-25 Sirna Therapeutics, Inc. Enzymatic nucleic acid-mediated treatment of ocular diseases or conditions related to levels of vascular endothelial growth factor receptor (VEGF-R)
US5807743A (en) * 1996-12-03 1998-09-15 Ribozyme Pharmaceuticals, Inc. Interleukin-2 receptor gamma-chain ribozymes
US6280936B1 (en) 1997-06-09 2001-08-28 Ribozyme Pharmaceuticals, Inc. Method for screening nucleic acid catalysts
US6548657B1 (en) 1997-06-09 2003-04-15 Ribozyme Pharmaceuticals, Inc. Method for screening nucleic acid catalysts
US6617438B1 (en) 1997-11-05 2003-09-09 Sirna Therapeutics, Inc. Oligoribonucleotides with enzymatic activity
US6482932B1 (en) 1997-11-05 2002-11-19 Ribozyme Pharmaceuticals, Incorporated Nucleoside triphosphates and their incorporation into oligonucleotides
US6995259B1 (en) 1998-10-23 2006-02-07 Sirna Therapeutics, Inc. Method for the chemical synthesis of oligonucleotides
US20070026394A1 (en) 2000-02-11 2007-02-01 Lawrence Blatt Modulation of gene expression associated with inflammation proliferation and neurite outgrowth using nucleic acid based technologies
US7125660B2 (en) 2000-09-13 2006-10-24 Archemix Corp. Nucleic acid sensor molecules and methods of using same
US20050148530A1 (en) 2002-02-20 2005-07-07 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US7205399B1 (en) 2001-07-06 2007-04-17 Sirna Therapeutics, Inc. Methods and reagents for oligonucleotide synthesis
US20030195164A1 (en) * 2002-04-16 2003-10-16 Veli-Matti Kahari Novel ribozyme and its use
WO2010052649A1 (en) * 2008-11-04 2010-05-14 South African Medical Research Council Oligonucleotides and methods for determining susceptibility to soft tissue injuries

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5272263A (en) * 1989-04-28 1993-12-21 Biogen, Inc. DNA sequences encoding vascular cell adhesion molecules (VCAMS)
EP1251170A3 (de) * 1992-07-17 2002-10-30 Ribozyme Pharmaceuticals, Inc. Vergahren und Reagenz zur Behandlung von NF-kappaB abhängiger Tierischen Krankheiten

Also Published As

Publication number Publication date
EP0728205A1 (de) 1996-08-28
EP0728205B1 (de) 2002-10-16
WO1995013380A2 (en) 1995-05-18
JPH09504949A (ja) 1997-05-20
DE69431564D1 (de) 2002-11-21
AU1097395A (en) 1995-05-29
CA2175824A1 (en) 1995-05-18
WO1995013380A3 (en) 1995-06-22
AU704687B2 (en) 1999-04-29

Similar Documents

Publication Publication Date Title
ATE226254T1 (de) Reagenz zur behandlung von arthritischen zustaenden
BR9908280A (pt) Inibidores de enzimas de fosfolipase
DE69633679D1 (de) Substituierte aryl-oder heteroarylamide mit retinoid-ähnlicher biologischer aktivität
EP0654077A4 (de) Methode und reagenz zur behandlung einer tierischen krankheit.
DE69432298D1 (de) System zur diagnostik und behandlung der prostata und der harnwege
DE60015070D1 (de) Verwendung von antikonvulsiven derivaten zur behandlung der cluster headache
EA199900758A1 (ru) Малые молекулы, полезные при лечении воспалительных заболеваний
DE59509510D1 (de) System zur Inkubation von Probeflüssigkeiten
EA199700087A1 (ru) Способ ингибирования катепсина к
DE69434511D1 (de) Botulinumtoxin zur Behandlung von Dystonie
ATE307592T1 (de) Epiallopregnanolon zur behandlung von krankheiten des cns
ATE203545T1 (de) Substrate und inhibitoren von proteolytischen enzymen
EA200000196A1 (ru) Универсальная плазма крови
DE69835419D1 (de) Verfahren zur Behandlung von organischem Abwasser
DE69837153D1 (de) Verhinderung des zellwachstums in einem gewässer
DE29605625U1 (de) Anlage zur Vergärung von organischen Abfallstoffen
ATE356212T1 (de) O-fukosyltransferase
TR200000150T2 (tr) Amidlerin elde edilmesine mahsus usul.
DE69536133D1 (de) Methode zur Reinigung von Keratinozyten-Wachstumfaktoren
DE50213120D1 (de) Mikrobiologisches verfahren zur herstellung von amiden
DE261607T1 (de) Biozide mittel zur behandlung gewerblicher abwaesser, insbesondere gaswascherschlaemme.
MXPA03011715A (es) Moleculas de agrecanasa.
DE3773875D1 (de) Methode zur hemmung der multiplikation des bacillus cereus.
PT1129206E (pt) Dissolucao de substancias residuais de fermentacao
PT1196606E (pt) Enzima litica

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties